Medeor Therapeutics Raises $57 Million In Series B Financing
This financing will support the Phase 3 clinical trial of MDR-101 in living donor HLA-matched kidney transplant patients, being conducted under a Special Protocol Agreement with the
"Organ transplantation is one of the most remarkable life-giving feats of modern medicine, though patients must deal with intense and sometimes intolerable chronic immune suppression," said
"
"Since Medeor's inception, we have worked to bring our potentially transformative programs to the point of pivotal clinical trials," said
About
Medeor Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients.
About
About
Founded in 1974, Sofinnova specializes in clinical and late preclinical investments in biopharmaceutical products. Our goal is to actively partner with entrepreneurs across all stages of company development. We seek to build world class companies that aspire to dramatically improve the current state of medical care and the lives of patients through bringing innovative products to market. For more information, please visit www.sofinnova.com.
Contact
Chief Financial and Business Officer
[email protected]
View original content:http://www.prnewswire.com/news-releases/medeor-therapeutics-raises-57-million-in-series-b-financing-300561638.html
SOURCE
Missing American Military Personnel Identified After Plane Crash
Analysis Group Welcomes New Affiliates, Announces Consultant Promotions
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News